Mantle Cell Lymphoma Consortium and Initiative
In the early 2000s, limited federal and private resources were dedicated to the study of mantle cell lymphoma (MCL). MCL is a rare, typically aggressive form of non-Hodgkin lymphoma (NHL) which accounts for roughly six percent of all NHL cases in the United States. Recognizing that a targeted research focus on MCL would benefit this underserved and understudied patient population, the Lymphoma Research Foundation (LRF) began awarding MCL-specific research grants and gathering its MCL grantees for a regular scientific meeting to report on their findings and form collaborations.
As the LRF MCL research program grew, so did the meeting and requests from scientists who wished to attend. Recognizing the importance of this meeting and LRF’s role as the world’s largest private funder of MCL research, the LRF Mantle Cell Lymphoma Consortium (MCLC) was formed and the annual meeting – now a global scientific workshop – and the research infrastructure created by LRF was opened to MCL researchers from around the world. The MCLC is now composed of almost 150 international laboratory and clinical scientists whose research is focused on MCL.
LRF has convened its Mantle Cell Lymphoma Scientific Workshop since 2003. The goal of the biennial Workshop is to bring together the world’s leading experts in mantle cell lymphoma (MCL) to discuss the latest research findings, receive updates on the progress of LRF grantees, foster collaboration within the MCL research community, create a direction for MCL research, and ultimately improve MCL diagnosis and treatment for patients. Abstracts and presentations for the Workshop are sought across the following categories:
- MCL Biology
- MCL Novel Pathways and Targets
- MCL Therapeutic Resistance and Personalization of Therapy
- MCL Epidemiology and Outcomes Research
- MCL Prognostic and Predictive Biomarkers
- MCL Clinical Trials
In addition, a keynote address is offered by a global thought leader in the field of MCL research, and expert debates are staged to discuss pivotal topics in the treatment and care of people with MCL. After the conclusion of the Workshop, LRF and its scientific advisors publish a proceedings paper highlighting the key themes and highlights from the Workshop. It is considered a blueprint for future MCL research and is sought out by researchers and clinicians worldwide. The Workshop and proceedings paper also informs LRF’s MCL patient education program, bringing the most up-to-date information on treatment options and clinical trials directly to patients. MCLC members serve as faculty for patient programs and develop all of LRF’s MCL patient resources and disease-specific literature.
Martin Dreyling, MD
University Hospital LMU Munich
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Tuebingen
Executive Members Emeritus
Steven Bernstein, MD
University of Rochester
Elias Campo, MD
University of Barcelona
Joseph Connors, MD
Randy Gascoyne, MD
Pedro Jares, PhD, IDIBAPS
University of Barcelona
Brad Kahl, MD
Washington University in St. Louis
John P. Leonard, MD
Weill Cornell Medicine
Owen O’Connor, MD, PhD
Michael Williams, MD
University of Virginia Health System
Thomas Witzig, MD
- “Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.” Leukemia & Lymphoma. December 2010.
- “2016 Mantle Cell Lymphoma Workshop Highlights Advances in Treatment.” Research Report. Summer 2016.
- “Clinical, Laboratory Advances Highlighted at 2018 Mantle Cell Lymphoma Workshop.” Research Report. Summer 2018.
- “Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.” Leukemia & Lymphoma. January 2019.